The week in pharma: action, reaction and insight – week to August 12

14 August 2022

By Barbara Obstoj-Cardwell. Managing editor

Confirming earlier rumors, last Monday UK pharma giant Pfizer revealed it has entered into a $5.4 billion deal to acquire Global Blood Therapeutics, along with its sickle cell disease gene therapy Oxbryta. The US Food and Drug Administration (FDA) last week granted approval for Myovant and Pfizer’s Myfembree for the treatment of severe pain associated with endometriosis. Last Tuesday Mersana Therapeutics entered into a licensing agreement with GSK, with the UK pharma major taking an option on its Immunosynthen ADC, XMT-2056 that could earn Mersana as much as $1.36 billion. Also last week, fears of Zantac side-effect financial liability lawsuits impacted several pharma majors, including GSK and Sanofi, wiping billions off their marker capitalization.

Pfizer bets $5.4 billion against gene therapies in sickle cell

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK